Invention Application
- Patent Title: AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
-
Application No.: US17244938Application Date: 2021-04-29
-
Publication No.: US20220356180A1Publication Date: 2022-11-10
- Inventor: Ryan M. Moslin , David S. Weinstein , Stephen T. Wrobleski , John S. Tokarski , Amit Kumar , Douglas G. Batt , Shuqun Lin , Chunjian Liu , Steven H. Spergel , Yanlei Zhang , Qingjie Liu
- Applicant: Bristol-Myers Squibb Company
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Main IPC: C07D417/14
- IPC: C07D417/14 ; C07D403/12 ; C07D401/14 ; C07D413/14 ; C07D401/12 ; C07D237/24 ; C07D403/14 ; C07D413/12 ; C07D417/12 ; C07B59/00
Abstract:
Compounds having the following formula I. or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.
Information query
